Inlecitug

Inlecitug is a chimeric monoclonal antibody that targets the human KDR (kinase insert domain receptor) . By specifically binding to KDR, Inlecitug blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, thereby inhibiting angiogenesis and exerting antitumor activity. Inlecitug holds potential for cancer research.